Aeterna Zentaris

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company, which engages in the development of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

COSCIENS Biopharma Inc. Is a specialty biopharmaceutical company, which engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Canada.

TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Pharmanovia, a global lifecycle management healthcare company, has acquired from the Company's existing EEA and UK partner, Consilient Health, the exclusive rights and license to commercialize GHRYVELIN™ (macimorelin) in the territory for the diagnosis of Adult Growth Hormone Deficiency (AGHD) and, if approved, for Childhood Onset Growth Hormone Deficiency (CGHD).

Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)

Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?

TORONTO, ONTARIO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today provided a business update and outlined upcoming key milestones.

Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones

Live video webcast on Thursday , January 19 th at 3 :00 PM ET

Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -2.94% and 38.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aeterna Zentaris (AEZS) Reports Q3 Loss, Tops Revenue Estimates

– Company ended the quarter with $ 53.8 million in cash

Aeterna Zentaris Reports Third Quarter 2022 Financial Results

– Company plans to prioritize efforts to identify new strategic development and commercialization partner

Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk

– Company ended the quarter with $58.2 million in cash

Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights

TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that the proposed consolidation of the Company's shares (the “Share Consolidation”) was approved at its reconvened annual meeting of shareholders (the “Meeting”) held today.

Aeterna Zentaris Announces Shareholder Approval of Share Consolidation

TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that the Company has further adjourned its annual general and special meeting of shareholders (the "Meeting"). The Meeting was originally held on June 21, 2022, and was reconvened and further adjourned today prior to shareholders voting on the proposed consolidation of the Company's common shares (the "Share Consolidation").

Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting

- Vote to approve share consolidation adjourned to July 6, 2022

Aeterna Zentaris Announces Results of Annual Meeting of Shareholders

TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference

– Data presented at IMMUNOLOGY2022 ™ , the A nnual Event of the American Association of Immunologists

Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson's Disease

– C ontinue d advancement across di versified development pipeline

Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook

– Company advancing development of its Autoimmunity Modifying AIM Biologic al s as a potential therapeutic treatment option for Parkinson's Disease (" PD "), a neurodegenerative movement disorder

Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists

– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin ® / Macrilen ™ in Europe as the Company plans to pursue even greater protection

Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults

American Resources Corp

CNS Pharmaceuticals

- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the continuation of its Virtual Investor Spotlight Series to be held on Thursday, April 14, 2022. Access the full series of events here.

JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC

– Live moderated video webcast fireside chat with Dr. Klaus Paulini , CEO and Giuliano La Fratta, CFO of Aeterna Zentaris, on Thursday , April 14th at 10 :00 AM ET

Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight

– Company to present regarding AIM Biologic al s as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD"), an orphan indication with strong unmet medical need

Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity

– Company actively monitoring delays to mitigate potential impact of COVID-19 and conflict in Ukraine following Russian invasion on the estimated completion dates for the trial

Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

– R esearch agreement expanded for development of human 3D intestinal tissue models to study Salmonella enterica pathogenesis

Aeterna Zentaris Announces Expansion of Research Program with Julius-Maximilians-University Wuerzburg Aiming to Accelerate Development of Vaccine Programs

– Notice of allowance received by Company's l icensor, The University of Sheffield (UK) bolsters intellectual property of AEZS-150 in development for the potential treatment of chronic hypoparathyroidism –

Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism

CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna Zentaris, will present at the BIO CEO & Investor Conference being held in New York, NY and virtually, February 14-17, 2022.

Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference

CHARLESTON, S.C., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") has notified the Company that it has been granted an additional 180 calendar day period, through July 23, 2022, to evidence compliance with the US$1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

– Company advancing diversified portfolio focused on areas of significant unmet medical need – Supported by solid financial position with cash to fund operations beyond 2023

News for Aeterna Zentaris Stock (AEZS)